Aeterna Zentaris (AEZS) Perifosine Phase 2 Data in mCRC Patients Published
Tweet
Share
E-mailGet Alerts AEZS Hot Sheet
Join SI Premium – FREE
Aeterna Zentaris Inc. (Nasdaq: AEZS), reports a manuscript entitled, "Randomized Placebo-Controlled Phase 2 Trial of Perifosine Plus Capecitabine as Second- or Third-Line Therapy in Patients with Metastatic Colorectal Cancer " reporting Phase 2 activity of perifosine (KRX-0401) in the treatment of patients with refractory, advanced colorectal cancer (mCRC), was selected for publication in the October 3, 2011 online edition of the Journal of Clinical Oncology (JCO).
Perifosine, the Company's Akt/PI3K inhibitor, is currently being investigated in a Phase 3 trial entitled the "X-PECT" (Xeloda + Perifosine Evaluation in Colorectal cancer Treatment), which is a randomized (1:1), double-blind trial comparing the efficacy and safety of perifosine + capecitabine vs. placebo + capecitabine. In July, the Company announced the completion of enrolment of the Phase 3 X-PECT study, with approximately 465 patients in the United States randomized. Approximately 360 events of death will trigger the un-blinding of the study. Study completion is expected in Q112.
KRX-0401 (perifosine) is in-licensed by Keryx (Nasdaq: KERX) from Aeterna Zentaris Inc. (NASDAQ: AEZS) in the United States, Canada and Mexico.
Perifosine, the Company's Akt/PI3K inhibitor, is currently being investigated in a Phase 3 trial entitled the "X-PECT" (Xeloda + Perifosine Evaluation in Colorectal cancer Treatment), which is a randomized (1:1), double-blind trial comparing the efficacy and safety of perifosine + capecitabine vs. placebo + capecitabine. In July, the Company announced the completion of enrolment of the Phase 3 X-PECT study, with approximately 465 patients in the United States randomized. Approximately 360 events of death will trigger the un-blinding of the study. Study completion is expected in Q112.
KRX-0401 (perifosine) is in-licensed by Keryx (Nasdaq: KERX) from Aeterna Zentaris Inc. (NASDAQ: AEZS) in the United States, Canada and Mexico.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sky Quarry names Heidi Bowman as CFO
- Robo.ai names Hao Wang of Changer.ae to its board of directors
- AAON rebrands its enterprise identity as The Aaon Group
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
